VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression

Blood

Volumn 101, Issue 12, 2003, Pages 4878-4886

  Ohm, Joyce E ^a   Gabrilovich, Dmitry I ^b   Sempowski, Gregory D ^b   Kisseleva, Ekaterina ^b   Parman, Kelly S ^b   Nadaf, Sorena ^b   Carbone, David P ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE; CELL DENSITY; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HYPOTHESIS; INFUSION; MOUSE; NICK END LABELING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLYMPHOCYTE; RADIOIMMUNOASSAY; T LYMPHOCYTE; THYMOCYTE; THYMUS ATROPHY; TUMOR IMMUNOLOGY;

EID: 0037777538     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-1956     Document Type: Article

References (29)

1. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am. 1996;10:927-951.
2. Antonia SJ, Extermann M, Flavell RA. Immunologic nonresponsiveness logic non responsiveness to tumors. Crit Rev Oncog. 1998;9:35-41.
3. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999;20:158-160.
4. Johnsen AK, Templeton DJ, Sy M, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol. 1999;163:4224-4231.
5. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction [comment]. Cancer Immunol Immunother. 1999;48:353-362.
6. Markiewicz MA, Gajewski TF. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999;10:247-260.
7. Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog. 1997;8:111-141.
8. Shu S, Plautz GE, Krauss JC, Chang AE. Tumor immunology. JAMA. 1997;278:1972-1981.
9. Pawelec G, Effros RB, Caruso C, Remarque E, Barnett Y, Solana R. T cells and aging [update February 1999]. Front Biosci. 1999;4:D216-D269.
10. Zhang M. The relationships between thymus, other immune organs and various diseases in children (analysis of 621 cases). Chung-Hua Ping Li Hsueh Tsa Chih (Chin J Pathol). 1989;18:92-95.
11. Adkins B, Charyulu V, Suri QL, Lobo D, Lopez DM. Early block in maturation is associated with thymic involution in mammary tumor-bearing mice. J Immunol. 2000;164:5635-5640.
12. Fu Y, Paul RD, Wang Y, Lopez DM. Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. J Immunol. 1989;143:4300-4307.
13. Lee MY, Rosse C. Depletion of lymphocyte subpopulations in primary and secondary lymphoid organs of mice by a transplanted granulocytosis-inducing mammary carcinoma. Cancer Res. 1982;42:1255-1260.
14. Thomas E, Smith DC, Lee MY, Rosse C. Induction of granulocytic hyperplasia, thymic atrophy, and hypercalcemia by a selected subpopulation of a murine mammary adenocarcinoma. Cancer Res. 1985;45:5840-5844.
15. Kaiserlian D, Savino W, Hassid J, Dardenne M. Studies of the thymus in mice bearing the Lewis lung carcinoma, III: possible mechanisms of tumor-induced thymic atrophy. Clin Immunol Immunopathol. 1984;32:316-325.
16. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
17. Ziegler BL, Valtieri M, Porada GA, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999;285:1553-1558.
18. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [erratum appears in Nat Med. 1996;11:1267]. Nat Med. 1996;2:1096-1103.
19. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
20. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970.
21. Sempowski GD, Gooding ME, Liao HX, Le PT, Haynes BF. T cell receptor excision circle assessment of thymopoiesis in aging mice. Mol Immunol. 2002;38:841-848.
22. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1:661-673.
23. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996;273:242-245.
24. Kondo M, Scherer DC, Miyamoto T, et al. Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature. 2000;407:383-386.
25. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
26. Yasuda Y, Kaneko A, Nishijima I, Miyatake S, Arai K. Interleukin-7 inhibits pre-T-cell differentiation induced by the pre-T-cell receptor signal and the effect is mimicked by hGM-CSF in hGM-CSF receptor transgenic mice. Immunology. 2002;106:212-221.
27. Freitas CS, Dalmau SR, Kovary K, Savino W. Epidermal growth factor modulates fetal thymocyte growth and differentiation. Dev Immunol. 1998;5:169-182.
28. Foss DL, Donskoy E, Goldschneider I. The importation of hematogenous precursors by the thymus is a gated phenomenon in normal adult mice. J Exp Med. 2001;193:365-374.
29. + cells at a diverging point of endothelial and hemopoietic lineages. Development. 1998;125:1747-1757.